Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes

Abstract

Objective: To observe the clinical efficacy of thymosin alpha 1 (Tα1) combined with multi-modality chemotherapy in patients with pulmonary tuberculosis (PTB) complicated with diabetes and discuss the effects of such combination therapy on lymphocyte subsets and sputum levels of cytokines.
 Methods: A total of 120 patients with PTB complicated with diabetes admitted to the Affiliated Hospital of North China University of Science and Technology from January 2017 to January 2018 were included in this study and randomly divided into an experimental group (Tα1 group, n=60) and a control group (n=60). Clinical efficacy and adverse drug reactions were observed and compared between the two groups. Blood samples were collected for lymphocyte (NK cell and T cell subsets) levels by flow cytometry, and sputum samples were collected for cytokine (IL-2, IFN-γ, IL-4 and TNF-α) levels by ELISA.
 Results: Two groups showed no statistically significant difference in sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate (P>0.05) after 6 months of treatment. However, after 12 months, the sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate in the Tα1 group increased compared with the control group, and the differences were statistically significant (P<0.05). There was a significant increase in CD3+, CD4+, NK-cells lymphocytes after six months in the Tα1 group than in the control group, whereas the CD8+, Th17, Treg lymphocytes in the Tα1 group were substantially lower than in the control group, with the differences showing statistical significance (P<0.05, respectively). After six months of treatment, the sputum supernatant levels of interleukin-4 (IL-4) and tumor necrosis factor α (TNF-α) in the Tα1 group were lower than in the control group, whereas the sputum supernatant levels of interleukin-2 (IL-2) and interferon gamma (IFN-γ) in the Tα1 group were higher than in the control group, and the differences were statistically significant (P<0.05, respectively). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).
 Conclusion: Tα1 combined with multi-modality chemotherapy has a visible curative effect on PTB patients with diabetes as it can regulate immune function and reduce the levels of inflammatory cytokines. As a safe combination therapy, it seems promising for further use in clinical practice.
 doi: https://doi.org/10.12669/pjms.38.1.4419
 How to cite this:Wu L, Luo P, Tian Y, Chen L, Zhang Y. Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes. Pak J Med Sci. 2022;38(1):---------. doi: https://doi.org/10.12669/pjms.38.1.4419
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Impaired interferon-γ signaling promotes the development of silicosis

“…Interestingly, thymosin alpha 1, a naturally occurring polypeptide with an excellent safety profile in the clinic, significantly attenuates disease severity in murine model of cystic fibrosis, a genetic disease lung fibrosis ( Wandel et al., 2020 ). In addition, thymosin alpha 1 has been proved to promote the IFN-γ production in the respiratory tract of pulmonary tuberculosis patients ( Wu et al., 2022 ). But whether thymosin alpha 1 administration could prevent the development of silicosis in workers with inhaled crystalline silica exposure merits future studies.…”

Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application

“…Furthermore, Tα1 can affect immune function by inducing and regulating the maturation of T and NK cells, activating lymphocytes, and regulating the secretion of inflammatory cytokines such as IL-2, IL-4, IFN-γ, TNF-α, et al [41,44,45]. Upon binding to TLR receptors located on the surface of precursor T cells, Tα1 promotes their differentiation into cytotoxic T lymphocytes (CD8 + T cells, CTL) [29,31,46].…”

The Effects of Thymosin Alpha-1 on Macrophages: A Cytological and Anti-Inflammatory Study

“…After 10 minutes of incubation, the absorption spectrum was recorded at 540 nm. The nitrite level was determined using a sodium nitrite calibration curve as a benchmark [20][21][22].…”

“…In addition, Tα-1 has been found to boost the physiological characteristics of Natural Killer (NK) cells in in-vivo system and also in HIV-positive individuals. This is significant, as NK activity tends to decrease in individuals with hepatitis C infections [4][5][6][7][8]. Furthermore, Tα-1 can promote the production of Th1 cytokines like IFN, IL-2, and IL-3, as well as the expression of IL-2 receptors, leading to a Th1 immunological response which is also linked with strong antiviral activity [9].…”